Limonene

Pharmacology & Research

Limonene is a monocyclic monoterpene — the molecule that gives citrus peel its scent, and one of the most abundant terpenes in nature. It exists as two mirror-image forms: D-limonene (R-(+)-limonene), the orange-scented enantiomer that dominates citrus peel oil and carries essentially all the human data, and L-limonene (S-(−)-limonene), the more turpentine/pine-scented form found in caraway and dill; unless stated otherwise, “limonene” below means the D-form. It turns up across this database as a minor-to-moderate component of volatile oils — buchu, juniper, fennel, peppermint, lemongrass and many others — and is a relative of the other volatile monoterpenes α-pinene, β-pinene and myrcene. Two things frame its evidence. First, limonene is unusual among plant terpenes in having genuine human data on the isolated molecule — a Phase I oncology trial, a pre-surgical breast-tissue study and small heartburn trials — rather than only whole-oil or rodent work. Second, and load-bearing: limonene is well absorbed but almost entirely first-pass-metabolised, appearing in blood mostly as the acids perillic acid and dihydroperillic acid plus limonene-1,2-diol, so much of its systemic pharmacology is really the pharmacology of those metabolites ^{1,5,6Reference 1Vigushin DM et al. · 1998Clinical trialPhase I and pharmacokinetic study of D-limonene in patients with advanced cancer — Phase I clinical trialView study →Reference 5Poon GK et al. · 1996Clinical trialIdentification and characterization of limonene metabolites in patients with advanced cancer by liquid chromatography/mass spectrometry — human PKView study →Reference 6Schmidt L · 2017R-Limonene metabolism in humans and metabolite kinetics after oral administration — human PK studyView study →}.

1. Cancer chemoprevention

The most human-tested line, and it is on the isolated molecule. In a Cancer Research Campaign Phase I trial, 32 patients with advanced cancer took oral D-limonene 0.5–12 g/m²/day in 21-day cycles; it was well tolerated (maximum tolerated dose 8 g/m²/day, dose-limiting nausea/vomiting/diarrhoea), one breast-cancer patient had a partial response sustained ~11 months, and three colorectal patients had prolonged stable disease ^{1Reference 1Vigushin DM et al. · 1998Clinical trialPhase I and pharmacokinetic study of D-limonene in patients with advanced cancer — Phase I clinical trialView study →}. A later pre-surgical (window-of-opportunity) study gave 43 women with early breast cancer 2 g/day of limonene for 2–6 weeks: it concentrated in breast tissue (mean ~41 µg/g, far above plasma) and significantly reduced tumour cyclin D1 expression, a proliferation driver — though it also nudged serum IGF-1 upward, a mixed signal over so short a window ^{2,3Reference 2Miller JA et al. · 2013Clinical trialHuman breast tissue disposition and bioactivity of limonene in women with early-stage breast cancer — pre-surgical clinical studyView study →Reference 3Miller JA et al. · 2015Plasma metabolomic profiles of breast cancer patients after short-term limonene intervention — human intervention studyView study →}. Preclinically, D-limonene and its metabolite perillyl alcohol are among the better-studied dietary chemopreventives across rodent mammary, liver and other models ^{17,18Reference 17Vieira AJ et al. · 2018ReviewLimonene: aroma of innovation in health and disease — reviewView study →Reference 18Anandakumar P et al. · 2021ReviewD-limonene: a multifunctional compound with potent therapeutic effects — reviewView study →}.

Gap: no randomised efficacy trial exists; the human data are a small Phase I and a short pre-surgical biomarker study, and the durable responses are anecdotal, not powered outcomes ^{1,2Reference 1Vigushin DM et al. · 1998Clinical trialPhase I and pharmacokinetic study of D-limonene in patients with advanced cancer — Phase I clinical trialView study →Reference 2Miller JA et al. · 2013Clinical trialHuman breast tissue disposition and bioactivity of limonene in women with early-stage breast cancer — pre-surgical clinical studyView study →}.

2. GERD / heartburn

The most cited “practical” use — and among the weakest evidence. Small human trials (originating in a 2002 US patent and summarised in the D-limonene safety monograph) report that intermittent oral D-limonene — commonly one 1,000 mg capsule every other day — reduced or eliminated heartburn in most participants, sometimes for weeks after a short course; one arm was a small double-blind placebo comparison (7 active vs 6 placebo) ^{7Reference 7Sun J · 2007ReviewD-Limonene: safety and clinical applications — reviewView study →}. The proposed mechanism is neutralising/“floating” reflux and promoting oesophageal clearance rather than acid suppression, but this is not established.

Gap: the trials are tiny, largely uncontrolled, patent-linked and never replicated in a large, independent, high-quality study; the heartburn indication should be read as plausible-but-unproven ^{7Reference 7Sun J · 2007ReviewD-Limonene: safety and clinical applications — reviewView study →}.

3. Anxiolytic / mood

A coherent preclinical signal, from both inhaled and oral dosing. Isolated limonene showed anti-anxiety activity in mice that was blocked by an adenosine A2A-receptor antagonist, working through A2A-mediated regulation of striatal dopamine and GABA release ^{8Reference 8Song Y et al. · 2021AnimalLimonene has anti-anxiety activity via adenosine A2A receptor-mediated regulation of dopaminergic and GABAergic neuronal function in the striatum — mouse in vivoView study →}. Separately, inhaled sweet-orange (Citrus sinensis) essential oil and its main component limonene reversed depression-like behaviour in a chronic-mild-stress mouse model, dampening HPA-axis hyperactivity and restoring monoamine neurotransmitters and hippocampal BDNF signalling ^{9Reference 9Zhang LL et al. · 2019AnimalAntidepressant-like effect of Citrus sinensis (L.) Osbeck essential oil and its main component limonene on mice — mouse in vivoView study →}. This is the mechanistic basis behind the “calming/uplifting citrus” reputation in aromatherapy.

Gap: all rodent; no controlled human anxiety or depression trial of isolated limonene, and inhaled-oil studies confound the molecule with the whole oil ^{8,9Reference 8Song Y et al. · 2021AnimalLimonene has anti-anxiety activity via adenosine A2A receptor-mediated regulation of dopaminergic and GABAergic neuronal function in the striatum — mouse in vivoView study →Reference 9Zhang LL et al. · 2019AnimalAntidepressant-like effect of Citrus sinensis (L.) Osbeck essential oil and its main component limonene on mice — mouse in vivoView study →}.

4. Metabolic (lipids & glucose)

Isolated D-limonene improves metabolic markers in diet-stressed rodents. In high-fat-diet mice, D-limonene (given preventively or therapeutically) lowered fasting glucose, serum triglycerides and LDL, raised HDL, improved glucose tolerance and reduced hepatic lipid accumulation — effects tied to activating PPARα and inhibiting LXRβ signalling ^{10Reference 10Jing L et al. · 2013AnimalPreventive and ameliorating effects of citrus D-limonene on dyslipidemia and hyperglycemia in mice with high-fat diet-induced obesity — mouse in vivoView study →}. In high-fat/L-NAME rats, dietary D-limonene alleviated insulin resistance and oxidative liver injury ^{11Reference 11Santiago JV et al. · 2012AnimalDietary d-limonene alleviates insulin resistance and oxidative stress-induced liver injury in high-fat diet and L-NAME-treated rats — rat in vivoView study →}.

Gap: rodent models only, at dietary-supplement-scale doses that don’t clearly translate to a human metabolic dose; no human metabolic trial of the isolate ^{10,11Reference 10Jing L et al. · 2013AnimalPreventive and ameliorating effects of citrus D-limonene on dyslipidemia and hyperglycemia in mice with high-fat diet-induced obesity — mouse in vivoView study →Reference 11Santiago JV et al. · 2012AnimalDietary d-limonene alleviates insulin resistance and oxidative stress-induced liver injury in high-fat diet and L-NAME-treated rats — rat in vivoView study →}.

5. Anti-inflammatory / antioxidant

The broadest but thinnest basket. In human osteoarthritic chondrocytes, isolated limonene (tested alongside myrcene and β-caryophyllene) reduced IL-1β-driven nitric-oxide production and catabolic signalling, a genuine human-cell anti-inflammatory result ^{12Reference 12Rufino AT et al. · 2015In vitroEvaluation of the anti-inflammatory, anti-catabolic and pro-anabolic effects of E-caryophyllene, myrcene and limonene in a cell model of osteoarthritis — in vitro (human chondrocytes)View study →}. More broadly, limonene is a radical scavenger and features across in-vitro and rodent antioxidant, gastroprotective and antimicrobial assays summarised in the pharmacology reviews ^{17,18Reference 17Vieira AJ et al. · 2018ReviewLimonene: aroma of innovation in health and disease — reviewView study →Reference 18Anandakumar P et al. · 2021ReviewD-limonene: a multifunctional compound with potent therapeutic effects — reviewView study →}.

Gap: the human evidence is isolated-cell only; the in-vivo antioxidant/anti-inflammatory endpoints are rodent or in-vitro, with no clinical inflammation trial ^{12,17Reference 12Rufino AT et al. · 2015In vitroEvaluation of the anti-inflammatory, anti-catabolic and pro-anabolic effects of E-caryophyllene, myrcene and limonene in a cell model of osteoarthritis — in vitro (human chondrocytes)View study →Reference 17Vieira AJ et al. · 2018ReviewLimonene: aroma of innovation in health and disease — reviewView study →}.

Mechanisms

Target / pathway	Effect	Relevant to
Cyclin D1 / cell-cycle (via perillyl-type metabolites)	↓ proliferation; isoprenylation/Ras interference in models	Cancer chemoprevention
Adenosine A2A → dopamine/GABA (striatum)	Anxiolytic; antagonist-reversible	Anxiolytic / mood
Monoamines, HPA axis, hippocampal BDNF	Restores 5-HT/NA/DA; dampens stress response	Mood / antidepressant-like
PPARα ↑ / LXRβ ↓	↓ hepatic lipogenesis, improved lipids & glucose	Metabolic
NF-κB / iNOS-NO (IL-1β-stimulated chondrocytes)	↓ inflammatory & catabolic mediators	Anti-inflammatory
Radical scavenging (antioxidant)	↓ lipid peroxidation, ↑ antioxidant defences	Antioxidant, gastroprotection

Pharmacokinetics

Limonene’s defining pharmacological fact is not poor absorption but extensive first-pass metabolism. It is lipophilic and well absorbed orally, but it is rapidly oxidised by cytochrome P450 — chiefly CYP2C9 and CYP2C19 (with CYP2C8/2C18/3A4 contributing) — via 6- and 7-hydroxylation to trans-carveol and perillyl alcohol, which are further oxidised to the circulating acids perillic acid and dihydroperillic acid, plus limonene-1,2-diol, uroterpenol and limonene-8,9-diol ^{4,6,7Reference 4Miyazawa M et al. · 2002In vitroMetabolism of (+)- and (−)-limonenes to respective carveols and perillyl alcohols by CYP2C9 and CYP2C19 in human liver microsomes — in vitro humanView study →Reference 6Schmidt L · 2017R-Limonene metabolism in humans and metabolite kinetics after oral administration — human PK studyView study →Reference 7Sun J · 2007ReviewD-Limonene: safety and clinical applications — reviewView study →}. In the Phase I trial, parent D-limonene peaked around 10–20 µM while perillic acid reached much higher plasma levels (~20–71 µM), i.e. the metabolites dominate systemic exposure ^{1,5Reference 1Vigushin DM et al. · 1998Clinical trialPhase I and pharmacokinetic study of D-limonene in patients with advanced cancer — Phase I clinical trialView study →Reference 5Poon GK et al. · 1996Clinical trialIdentification and characterization of limonene metabolites in patients with advanced cancer by liquid chromatography/mass spectrometry — human PKView study →}. In controlled human oral dosing, blood metabolites peak at ~1–2 h and clear with half-lives of roughly 0.7–2.5 h (limonene-1,2-diol slowest), and parent limonene is largely undetectable in blood by 5 h — the signature of rapid, near-complete first-pass conversion ^{6Reference 6Schmidt L · 2017R-Limonene metabolism in humans and metabolite kinetics after oral administration — human PK studyView study →}. The practical upshot: dosing limonene is effectively dosing perillic acid and the diols, so mechanistic work on “limonene” should be read against which species actually circulates.

Clinical trials

Limonene has real but sparse human trial activity, almost all in oncology chemoprevention — a Phase I dose-finding/PK study ^{1Reference 1Vigushin DM et al. · 1998Clinical trialPhase I and pharmacokinetic study of D-limonene in patients with advanced cancer — Phase I clinical trialView study →} and a pre-surgical breast-tissue biomarker study ^{2,3Reference 2Miller JA et al. · 2013Clinical trialHuman breast tissue disposition and bioactivity of limonene in women with early-stage breast cancer — pre-surgical clinical studyView study →Reference 3Miller JA et al. · 2015Plasma metabolomic profiles of breast cancer patients after short-term limonene intervention — human intervention studyView study →} — plus small, low-quality heartburn trials ^{7Reference 7Sun J · 2007ReviewD-Limonene: safety and clinical applications — reviewView study →}; there are no large efficacy RCTs for any indication, and the anxiolytic and metabolic data are entirely preclinical.

Last checked: July 2026.

Isolate vs. Plant Studies

Limonene sits at an unusually favourable point on the isolate-vs-plant spectrum for a volatile terpene: its human data genuinely use the purified molecule. The Phase I oncology trial dosed pharmaceutical-grade D-limonene ^{1Reference 1Vigushin DM et al. · 1998Clinical trialPhase I and pharmacokinetic study of D-limonene in patients with advanced cancer — Phase I clinical trialView study →}, the breast study gave 2 g/day of limonene as the isolate ^{2Reference 2Miller JA et al. · 2013Clinical trialHuman breast tissue disposition and bioactivity of limonene in women with early-stage breast cancer — pre-surgical clinical studyView study →}, and the heartburn trials used purified D-limonene capsules ^{7Reference 7Sun J · 2007ReviewD-Limonene: safety and clinical applications — reviewView study →} — none are whole-oil stand-ins. That said, most of the non-cancer mechanistic literature is mixed: the mood work runs both ways (isolated limonene in the A2A study ^{8Reference 8Song Y et al. · 2021AnimalLimonene has anti-anxiety activity via adenosine A2A receptor-mediated regulation of dopaminergic and GABAergic neuronal function in the striatum — mouse in vivoView study →}; whole sweet-orange oil plus its limonene component in the depression model ^{9Reference 9Zhang LL et al. · 2019AnimalAntidepressant-like effect of Citrus sinensis (L.) Osbeck essential oil and its main component limonene on mice — mouse in vivoView study →}), and much of the antimicrobial/antioxidant reputation rests on citrus and herb essential oils where limonene is only the major component, not the sole actor. On the source-herb pages here, limonene is almost always one terpene within a whole volatile oil (buchu, juniper, fennel, peppermint), so those findings describe the oils, not the molecule. Read the oncology and heartburn trials as evidence for limonene itself, and the aromatherapy/essential-oil literature as evidence for the oils.

Prevalence in Nature

Limonene is one of the most widely distributed monoterpenes in the plant kingdom, but its marquee reservoir is citrus peel: the cold-pressed peel oil of sweet orange (Citrus sinensis) is roughly 90–95% D-limonene, and it dominates the peel oils of lemon, lime, grapefruit and mandarin too ^{17,18Reference 17Vieira AJ et al. · 2018ReviewLimonene: aroma of innovation in health and disease — reviewView study →Reference 18Anandakumar P et al. · 2021ReviewD-limonene: a multifunctional compound with potent therapeutic effects — reviewView study →}. Beyond the Rutaceae, it is a major constituent of caraway and dill seed oil (largely as the (S)-(−) enantiomer, alongside carvone), celery seed, conifer needle and resin oils (Pinaceae, Cupressaceae — e.g. juniper berry oil, pine), and a minor-to-moderate terpene across Lamiaceae (peppermint), Apiaceae (fennel, angelica), Poaceae (lemongrass) and Cannabaceae (cannabis) volatile oils. The enantiomer split is characteristic: citrus and conifers make chiefly R-(+)-limonene (orange scent), while caraway, dill and spearmint biosynthesis runs through (S)-(−)-limonene ^{17Reference 17Vieira AJ et al. · 2018ReviewLimonene: aroma of innovation in health and disease — reviewView study →}.

Biosynthetically it is a textbook monoterpene, built in the plastid via the MEP pathway: the C10 precursor geranyl diphosphate is cyclised in a single committed step by a limonene synthase (a monoterpene cyclase — (R)-limonene synthase in citrus, (S)-limonene synthase in caraway/mint), making limonene the branch-point scaffold from which carvone, perillyl and carveol derivatives are elaborated ^{17Reference 17Vieira AJ et al. · 2018ReviewLimonene: aroma of innovation in health and disease — reviewView study →}. It is essentially a plant product; there is no established animal biosynthetic source, though it is ubiquitous enough in diet and environment to appear as a trace body metabolite.

Discovery & Synthesis

Limonene has been known as the principal terpene of citrus peel since the 19th century, when terpene chemistry was first systematised (the work associated with Otto Wallach, Nobel laureate 1910); its name derives from the French limon / lemon, and the optically inactive racemate was long known by the separate name “dipentene.” The two enantiomers were later resolved and their opposite scents — R-(+) “orange,” S-(−) “turpentine/lemon-herb” — became a classic teaching example of chirality and olfaction. No single first-total-synthesis is a landmark for limonene, because it has never needed to be synthesised commercially: it is produced in enormous industrial volume as a by-product of citrus-juice processing, recovered by cold-pressing or steam-distilling the spent peel, and sold both as food-grade D-limonene (flavour/fragrance) and as a “green” degreasing solvent replacing petroleum distillates. Global output runs to tens of thousands of tonnes a year, making limonene one of the highest-tonnage natural terpenes in commerce ^{17,18Reference 17Vieira AJ et al. · 2018ReviewLimonene: aroma of innovation in health and disease — reviewView study →Reference 18Anandakumar P et al. · 2021ReviewD-limonene: a multifunctional compound with potent therapeutic effects — reviewView study →}.

Patents: not yet researched (future patent-loop pass).

Toxicity & Safety

Limonene carries a low toxicity flag. D-limonene is listed as Generally Recognised As Safe (GRAS) as a flavouring, is consumed routinely in citrus-containing foods, and was well tolerated in humans across single and repeated dosing up to a year — including the grams-per-day Phase I oncology doses, where toxicity was limited to gastrointestinal upset at the very top of the range ^{1,7Reference 1Vigushin DM et al. · 1998Clinical trialPhase I and pharmacokinetic study of D-limonene in patients with advanced cancer — Phase I clinical trialView study →Reference 7Sun J · 2007ReviewD-Limonene: safety and clinical applications — reviewView study →}. The one historically alarming finding needs stating honestly and in proportion: high oral doses of D-limonene cause kidney tumours in male rats, but this is a male-rat-specific mechanism with no human counterpart. It works through α2u-globulin nephropathy — D-limonene’s metabolite binds α2u-globulin, a protein synthesised only by adult male rats, causing protein accumulation, tubular injury and, eventually, tumours ^{13,14Reference 13Lehman-McKeeman LD et al. · 1989Animald-Limonene-induced male rat-specific nephrotoxicity: evaluation of the association between d-limonene and α2u-globulin — rat mechanism studyView study →Reference 14Lehman-McKeeman LD · 1991AnimalThe presence of α2u-globulin is necessary for d-limonene promotion of male rat kidney tumors — rat mechanism studyView study →}. Humans (and female rats, and mice) do not make a protein that behaves this way, so IARC and the US EPA judged these tumours not predictive of human risk, and the D-limonene safety literature explicitly concludes it poses no mutagenic, carcinogenic or nephrotoxic hazard to people ^{7,15Reference 7Sun J · 2007ReviewD-Limonene: safety and clinical applications — reviewView study →Reference 15Flamm WG · 1991AnimalThe human relevance of the renal tumor-inducing potential of d-limonene in male rats: implications for risk assessment — risk-assessment reviewView study →}. This is a different situation from the sibling terpene myrcene, whose NTP carcinogenicity signal spans two species and both a kidney and a liver mechanism — limonene has no such multi-species signal.

The genuine day-to-day caution is skin sensitisation from oxidised limonene. Fresh limonene is at most a very weak contact allergen, but on exposure to air and light it autoxidises to hydroperoxides and other oxygenated products that are potent contact allergens — oxidised D-limonene is a common cause of positive patch tests among dermatitis patients — so limonene-rich oils should be stored cool and dark, kept sealed, and diluted for topical use ^{16Reference 16Karlberg AT · 1997Contact allergy to oxidized d-limonene among dermatitis patients — clinical patch-test studyView study →}. For drug interactions, the mechanistic flag is metabolic: limonene is oxidised by CYP2C9 and CYP2C19 ^{4Reference 4Miyazawa M et al. · 2002In vitroMetabolism of (+)- and (−)-limonenes to respective carveols and perillyl alcohols by CYP2C9 and CYP2C19 in human liver microsomes — in vitro humanView study →}, and at the high doses used in cancer studies limonene/perillyl compounds can perturb CYP-mediated metabolism, so an interaction with narrow-margin CYP2C substrates is theoretically plausible — but no clinically documented human interaction dataset exists for dietary or supplemental intake. Scope note: formal human interaction, and pregnancy/lactation exposure data for the isolated molecule are limited; the low-risk read applies to culinary and studied supplemental levels, not to bulk or undiluted essential-oil use.

Dosage

There is no established human supplement dose for limonene, and nothing here is a recommendation. The research doses vary enormously by purpose. Chemoprevention/oncology studies used grams per day: the Phase I trial escalated to a maximum tolerated 8 g/m²/day (with activity seen at those high doses) ^{1Reference 1Vigushin DM et al. · 1998Clinical trialPhase I and pharmacokinetic study of D-limonene in patients with advanced cancer — Phase I clinical trialView study →}, while the pre-surgical breast study used a much more modest 2 g/day for 2–6 weeks ^{2Reference 2Miller JA et al. · 2013Clinical trialHuman breast tissue disposition and bioactivity of limonene in women with early-stage breast cancer — pre-surgical clinical studyView study →}. The heartburn trials used roughly 1,000 mg every other day for about 20 days ^{7Reference 7Sun J · 2007ReviewD-Limonene: safety and clinical applications — reviewView study →}. The rodent metabolic and behavioural work used doses (mg/kg) that don’t translate directly to people ^{10,11Reference 10Jing L et al. · 2013AnimalPreventive and ameliorating effects of citrus D-limonene on dyslipidemia and hyperglycemia in mice with high-fat diet-induced obesity — mouse in vivoView study →Reference 11Santiago JV et al. · 2012AnimalDietary d-limonene alleviates insulin resistance and oxidative stress-induced liver injury in high-fat diet and L-NAME-treated rats — rat in vivoView study →}.

Because limonene is extensively converted to perillic acid and diols on absorption, the circulating exposure is largely its metabolites rather than limonene itself ^{5,6Reference 5Poon GK et al. · 1996Clinical trialIdentification and characterization of limonene metabolites in patients with advanced cancer by liquid chromatography/mass spectrometry — human PKView study →Reference 6Schmidt L · 2017R-Limonene metabolism in humans and metabolite kinetics after oral administration — human PK studyView study →}. These are doses studied in research and are not a personal recommendation.

References